162 related articles for article (PubMed ID: 27897005)
1. STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION.
Wiley LK; Vanhouten JP; Samuels DC; Aldrich MC; Roden DM; Peterson JF; Denny JC
Pac Symp Biocomput; 2017; 22():545-556. PubMed ID: 27897005
[TBL] [Abstract][Full Text] [Related]
2. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
Ramirez AH; Shi Y; Schildcrout JS; Delaney JT; Xu H; Oetjens MT; Zuvich RL; Basford MA; Bowton E; Jiang M; Speltz P; Zink R; Cowan J; Pulley JM; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
Pharmacogenomics; 2012 Mar; 13(4):407-18. PubMed ID: 22329724
[TBL] [Abstract][Full Text] [Related]
3. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.
Kubo K; Ohara M; Tachikawa M; Cavallari LH; Lee MTM; Wen MS; Scordo MG; Nutescu EA; Perera MA; Miyajima A; Kaneko N; Pengo V; Padrini R; Chen YT; Takahashi H
Pharmacogenomics J; 2017 Dec; 17(6):494-500. PubMed ID: 27503578
[TBL] [Abstract][Full Text] [Related]
4. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.
Chumnumwat S; Yi K; Lucksiri A; Nosoongnoen W; Chindavijak B; Chulavatnatol S; Sarapakdi A; Nathisuwan S
Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29243335
[TBL] [Abstract][Full Text] [Related]
5. Genetic determinants of variability in warfarin response after the dose-titration phase.
Iwuchukwu OF; Ramirez AH; Shi Y; Bowton EA; Kawai VK; Schildcrout JS; Roden DM; Denny JC; Stein CM
Pharmacogenet Genomics; 2016 Nov; 26(11):510-516. PubMed ID: 27632229
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.
Nagai R; Ohara M; Cavallari LH; Drozda K; Patel SR; Nutescu EA; Perera MA; Hernandez W; Kaneko N; Hibiya M; Takahashi H
Pharmacogenomics; 2015; 16(3):217-25. PubMed ID: 25712185
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
[TBL] [Abstract][Full Text] [Related]
8. Race influences warfarin dose changes associated with genetic factors.
Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
[TBL] [Abstract][Full Text] [Related]
10. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
Bargal SA; Kight JN; Augusto de Oliveira F; Shahin MH; Langaee T; Gong Y; Hamadeh IS; Cooper-DeHoff RM; Cavallari LH
Clin Transl Sci; 2021 Mar; 14(2):492-496. PubMed ID: 33278335
[TBL] [Abstract][Full Text] [Related]
11. Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.
Liu N; Irvin MR; Zhi D; Patki A; Beasley TM; Nickerson DA; Hill CE; Chen J; Kimmel SE; Limdi NA
Pharmacogenomics; 2017 Jul; 18(11):1059-1073. PubMed ID: 28686080
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
13. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
Drozda K; Wong S; Patel SR; Bress AP; Nutescu EA; Kittles RA; Cavallari LH
Pharmacogenet Genomics; 2015 Feb; 25(2):73-81. PubMed ID: 25461246
[TBL] [Abstract][Full Text] [Related]
14. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance.
Shahabi P; Scheinfeldt LB; Lynch DE; Schmidlen TJ; Perreault S; Keller MA; Kasper R; Wawak L; Jarvis JP; Gerry NP; Gordon ES; Christman MF; Dubé MP; Gharani N
Thromb Haemost; 2016 Aug; 116(2):337-48. PubMed ID: 27121899
[TBL] [Abstract][Full Text] [Related]
15. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.
Wang F; Guo J; Zhang A
J Cardiovasc Pharmacol; 2019 Mar; 73(3):127-135. PubMed ID: 30688796
[TBL] [Abstract][Full Text] [Related]
17. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
Perera MA; Gamazon E; Cavallari LH; Patel SR; Poindexter S; Kittles RA; Nicolae D; Cox NJ
Clin Pharmacol Ther; 2011 Mar; 89(3):408-15. PubMed ID: 21270790
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing warfarin dose requirements in African-Americans.
Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
Hernandez W; Gamazon ER; Aquino-Michaels K; Smithberger E; O'Brien TJ; Harralson AF; Tuck M; Barbour A; Cavallari LH; Perera MA
J Thromb Haemost; 2017 Apr; 15(4):735-743. PubMed ID: 28135054
[TBL] [Abstract][Full Text] [Related]
20. Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients.
Ndadza A; Cindi Z; Makambwa E; Chimusa E; Wonkam A; Kengne AP; Ntsekhe M; Dandara C
OMICS; 2019 Jan; 23(1):36-44. PubMed ID: 30566377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
